B55.2
Mucocutaneous leishmaniasis
Clinical Classification Guidelines
Medical Intelligence & Overview
Mucocutaneous leishmaniasis is a disease caused by the Leishmania parasite, mainly affecting the skin and mucous membranes. It is a form of leishmaniasis that can cause significant tissue destruction and disfigurement if not diagnosed and treated appropriately. The condition is prevalent in certain tropical and subtropical regions, especially where the Sandfly, the disease’s primary vector, is common. Recognizing the signs, understanding the causes, and knowing the available treatment options are crucial steps toward managing and preventing this disease.
Causes & Symptoms
Clinical Causes: Transmission occurs through the bites of infected female Sandflies, which carry the Leishmania parasites. Environmental factors such as living in or visiting endemic areas with high Sandfly populations. Poor housing conditions and proximity to forested or rural areas can increase exposure risk. Increased exposure due to occupational activities, such as farming or forestry work in endemic regions. Limited use of protective measures like bed nets or insect repellents in endemic regions.
Key Symptoms: Initial skin lesions: small, painless nodules that may develop into ulcers. Progression to mucous membrane involvement, leading to nasal, oral, or throat ulcers. Swelling and inflammation of surrounding tissues. Disfigurement of affected areas due to tissue destruction. Possible secondary bacterial infections due to open ulcers. In some cases, lesions may be localized, while in others, they can be widespread.
Diagnostic & Treatment
Diagnosis Path: Diagnosis of mucocutaneous leishmaniasis typically involves a combination of clinical examination and laboratory tests. These tests include:
Treatment Protocols: The management of mucocutaneous leishmaniasis involves several options depending on the severity, location of lesions, and available resources. Typical treatment approaches include:
Clinical Advice & FAQs
Billing Guidance
Is B55.2 a billable ICD-10 code?
Yes, B55.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report B55.2?
Clinical documentation must specify the nature of Mucocutaneous leishmaniasis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference